

BEFORE THE UNITED STATES
JUDICIAL PANEL ON MULTIDISTRICT LITIGATION

)	
)	
)	
In re Ozempic® (Semaglutide) Patent)	MDL No. _____
Litigation)	
)	
)	

REASONS WHY ORAL ARGUMENT SHOULD BE HEARD

Pursuant to Rule 11.1 (b) of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation (the “Panel”), Novo Nordisk A/S and Novo Nordisk Inc. (collectively “Novo Nordisk”) respectfully request oral argument on their Motion for Transfer of the Action to the District of Delaware Pursuant to 28 U.S.C. §1407 for Coordinated and Consolidated Pretrial Proceedings.

Oral argument will allow Novo Nordisk to further address the merits of this motion and any arguments made in opposition, thereby assisting the Panel in rendering a decision. Oral argument will allow the parties to respond to any inquires the Panel may have regarding the factual similarities of the pending Hatch-Waxman litigations, the burdens and challenges that litigating them separately will impose, the judicial efficiencies that will be realized through consolidation, and why Delaware is the appropriate transferee district. Finally, oral argument will ensure that the Panel has access to the views of all parties who wish to be heard in these six actions, including to update the Panel on any events that have occurred since briefing.

For all of the foregoing reasons, Novo Nordisk respectfully requests that the Panel grant its request for oral argument.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ Brian P. Egan

OF COUNSEL:

Jeffrey J. Oelke
Ryan P. Johnson
Robert E. Counihan
Laura T. Moran
FENWICK & WEST LLP
902 Broadway, Suite 14
New York, NY 10010-6035
(212) 430-2600

Jack B. Blumenfeld (#1014)
Brian P. Egan (#6227)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@morrisonichols.com
began@morrisonichols.com

James F. Companion (W. Va. Bar No. 790)
Sandra K. Law (W. Va. Bar No. 6071)
SCHRADER COMPANION DUFF & LAW, PLLC
401 Main Street Wheeling, WV 26003
(304) 233-3390
jfc@schraderlaw.com
skl@schraderlaw.com

*Attorney for Novo Nordisk Inc. and
Novo Nordisk A/S*

May 6, 2022